Skip to main content
Clinical Trials/DRKS00010197
DRKS00010197
Completed
Not Applicable

Retrospective analysis of clinical outcomes after switching from Ranibizumab to Aflibercept - Wet AMD, Aflibercept

Berner Augenklinik0 sites577 target enrollmentApril 29, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
macular degeneration
Sponsor
Berner Augenklinik
Enrollment
577
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 29, 2016
End Date
September 26, 2016
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Berner Augenklinik

Eligibility Criteria

Inclusion Criteria

  • Patients suffering from wet AMD requiring intravitreal therapy, either newly diagnosed (treatment\-naive) or pretreated with Ranibizumab in case of insufficient response or other reasons.

Exclusion Criteria

  • \- any systemic disease potentially worsening under therapy (i.e. recent history of stroke or myocardial infarct)
  • \- structural damage to the macula excluding functional gain
  • \- any systemic disease interfering with local situation (i.e. Diabetes with advanced diabetic retinopathy)

Outcomes

Primary Outcomes

Not specified

Similar Trials